nodes	percent_of_prediction	percent_of_DWPC	metapath
Trazodone—HRH1—atherosclerosis	0.412	1	CbGaD
Trazodone—CYP3A7—Simvastatin—atherosclerosis	0.0335	0.0807	CbGbCtD
Trazodone—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0335	0.0807	CbGbCtD
Trazodone—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0328	0.079	CbGbCtD
Trazodone—CYP3A7—Lovastatin—atherosclerosis	0.0328	0.079	CbGbCtD
Trazodone—CYP3A5—Rosuvastatin—atherosclerosis	0.027	0.0651	CbGbCtD
Trazodone—CYP3A5—Simvastatin—atherosclerosis	0.0251	0.0605	CbGbCtD
Trazodone—CYP3A5—Pravastatin—atherosclerosis	0.0246	0.0592	CbGbCtD
Trazodone—CYP3A5—Lovastatin—atherosclerosis	0.0246	0.0592	CbGbCtD
Trazodone—CYP2D6—Niacin—atherosclerosis	0.0195	0.047	CbGbCtD
Trazodone—ABCB1—Ezetimibe—atherosclerosis	0.0176	0.0424	CbGbCtD
Trazodone—ABCB1—Simvastatin—atherosclerosis	0.0164	0.0394	CbGbCtD
Trazodone—ABCB1—Lovastatin—atherosclerosis	0.016	0.0386	CbGbCtD
Trazodone—ABCB1—Pravastatin—atherosclerosis	0.016	0.0386	CbGbCtD
Trazodone—CYP2D6—Simvastatin—atherosclerosis	0.0154	0.0371	CbGbCtD
Trazodone—CYP2D6—Pravastatin—atherosclerosis	0.0151	0.0363	CbGbCtD
Trazodone—CYP2D6—Lovastatin—atherosclerosis	0.0151	0.0363	CbGbCtD
Trazodone—CYP3A4—Rosuvastatin—atherosclerosis	0.0105	0.0254	CbGbCtD
Trazodone—CYP3A4—Ezetimibe—atherosclerosis	0.0105	0.0254	CbGbCtD
Trazodone—CYP3A4—Simvastatin—atherosclerosis	0.0098	0.0236	CbGbCtD
Trazodone—CYP3A4—Pravastatin—atherosclerosis	0.00959	0.0231	CbGbCtD
Trazodone—CYP3A4—Lovastatin—atherosclerosis	0.00959	0.0231	CbGbCtD
Trazodone—HTR2A—arteriole—atherosclerosis	0.00149	0.187	CbGeAlD
Trazodone—HTR2A—vein—atherosclerosis	0.000886	0.112	CbGeAlD
Trazodone—Cetirizine—HRH1—atherosclerosis	0.000847	0.201	CrCbGaD
Trazodone—Hydroxyzine—HRH1—atherosclerosis	0.000654	0.155	CrCbGaD
Trazodone—HTR2A—hindlimb—atherosclerosis	0.000589	0.0742	CbGeAlD
Trazodone—HTR2A—appendage—atherosclerosis	0.000505	0.0636	CbGeAlD
Trazodone—Ziprasidone—HRH1—atherosclerosis	0.000416	0.0986	CrCbGaD
Trazodone—Jaundice—Simvastatin—atherosclerosis	0.000396	0.00371	CcSEcCtD
Trazodone—Flatulence—Rosuvastatin—atherosclerosis	0.000394	0.0037	CcSEcCtD
Trazodone—Erectile dysfunction—Niacin—atherosclerosis	0.000385	0.00361	CcSEcCtD
Trazodone—Erectile dysfunction—Pravastatin—atherosclerosis	0.000379	0.00356	CcSEcCtD
Trazodone—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000376	0.00353	CcSEcCtD
Trazodone—Weight increased—Pravastatin—atherosclerosis	0.000375	0.00352	CcSEcCtD
Trazodone—Weight decreased—Pravastatin—atherosclerosis	0.000373	0.0035	CcSEcCtD
Trazodone—Jaundice—Niacin—atherosclerosis	0.000363	0.00341	CcSEcCtD
Trazodone—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000362	0.0034	CcSEcCtD
Trazodone—Flushing—Lovastatin—atherosclerosis	0.000362	0.00339	CcSEcCtD
Trazodone—HTR2A—artery—atherosclerosis	0.000361	0.0455	CbGeAlD
Trazodone—Myocardial infarction—Pravastatin—atherosclerosis	0.00036	0.00338	CcSEcCtD
Trazodone—Jaundice—Pravastatin—atherosclerosis	0.000358	0.00336	CcSEcCtD
Trazodone—Sweating—Niacin—atherosclerosis	0.000357	0.00335	CcSEcCtD
Trazodone—Flushing—Ezetimibe—atherosclerosis	0.000355	0.00333	CcSEcCtD
Trazodone—Zuclopenthixol—HRH1—atherosclerosis	0.000352	0.0834	CrCbGaD
Trazodone—Chills—Lovastatin—atherosclerosis	0.00035	0.00328	CcSEcCtD
Trazodone—Alopecia—Lovastatin—atherosclerosis	0.000344	0.00323	CcSEcCtD
Trazodone—Arthralgia—Rosuvastatin—atherosclerosis	0.000341	0.0032	CcSEcCtD
Trazodone—Myalgia—Rosuvastatin—atherosclerosis	0.000341	0.0032	CcSEcCtD
Trazodone—Flushing—Simvastatin—atherosclerosis	0.000338	0.00317	CcSEcCtD
Trazodone—Alopecia—Ezetimibe—atherosclerosis	0.000338	0.00317	CcSEcCtD
Trazodone—Flatulence—Lovastatin—atherosclerosis	0.000334	0.00314	CcSEcCtD
Trazodone—Hypoaesthesia—Niacin—atherosclerosis	0.000333	0.00312	CcSEcCtD
Trazodone—Dysgeusia—Lovastatin—atherosclerosis	0.000332	0.00312	CcSEcCtD
Trazodone—Confusional state—Rosuvastatin—atherosclerosis	0.000329	0.00309	CcSEcCtD
Trazodone—Back pain—Lovastatin—atherosclerosis	0.000328	0.00308	CcSEcCtD
Trazodone—Hypoaesthesia—Pravastatin—atherosclerosis	0.000328	0.00308	CcSEcCtD
Trazodone—Flatulence—Ezetimibe—atherosclerosis	0.000328	0.00308	CcSEcCtD
Trazodone—Chills—Simvastatin—atherosclerosis	0.000327	0.00307	CcSEcCtD
Trazodone—Aripiprazole—HRH1—atherosclerosis	0.000325	0.0771	CrCbGaD
Trazodone—Visual impairment—Niacin—atherosclerosis	0.000323	0.00303	CcSEcCtD
Trazodone—Alopecia—Simvastatin—atherosclerosis	0.000322	0.00302	CcSEcCtD
Trazodone—Back pain—Ezetimibe—atherosclerosis	0.000322	0.00302	CcSEcCtD
Trazodone—Vision blurred—Lovastatin—atherosclerosis	0.00032	0.003	CcSEcCtD
Trazodone—Tremor—Lovastatin—atherosclerosis	0.000318	0.00298	CcSEcCtD
Trazodone—Visual impairment—Pravastatin—atherosclerosis	0.000318	0.00298	CcSEcCtD
Trazodone—Ill-defined disorder—Lovastatin—atherosclerosis	0.000315	0.00295	CcSEcCtD
Trazodone—Flatulence—Simvastatin—atherosclerosis	0.000313	0.00293	CcSEcCtD
Trazodone—Tinnitus—Niacin—atherosclerosis	0.000312	0.00293	CcSEcCtD
Trazodone—Dysgeusia—Simvastatin—atherosclerosis	0.000311	0.00292	CcSEcCtD
Trazodone—Flushing—Niacin—atherosclerosis	0.000311	0.00291	CcSEcCtD
Trazodone—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000309	0.0029	CcSEcCtD
Trazodone—Anaemia—Ezetimibe—atherosclerosis	0.000308	0.00289	CcSEcCtD
Trazodone—Tinnitus—Pravastatin—atherosclerosis	0.000307	0.00288	CcSEcCtD
Trazodone—Malaise—Lovastatin—atherosclerosis	0.000306	0.00287	CcSEcCtD
Trazodone—Flushing—Pravastatin—atherosclerosis	0.000306	0.00287	CcSEcCtD
Trazodone—HTR2A—endothelium—atherosclerosis	0.000305	0.0384	CbGeAlD
Trazodone—Vertigo—Lovastatin—atherosclerosis	0.000305	0.00286	CcSEcCtD
Trazodone—Chills—Niacin—atherosclerosis	0.0003	0.00282	CcSEcCtD
Trazodone—Malaise—Ezetimibe—atherosclerosis	0.0003	0.00282	CcSEcCtD
Trazodone—Vision blurred—Simvastatin—atherosclerosis	0.000299	0.00281	CcSEcCtD
Trazodone—Arrhythmia—Niacin—atherosclerosis	0.000299	0.00281	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000298	0.00279	CcSEcCtD
Trazodone—Tremor—Simvastatin—atherosclerosis	0.000297	0.00279	CcSEcCtD
Trazodone—Alopecia—Niacin—atherosclerosis	0.000296	0.00278	CcSEcCtD
Trazodone—Chills—Pravastatin—atherosclerosis	0.000296	0.00277	CcSEcCtD
Trazodone—Insomnia—Rosuvastatin—atherosclerosis	0.000296	0.00277	CcSEcCtD
Trazodone—Ill-defined disorder—Simvastatin—atherosclerosis	0.000294	0.00276	CcSEcCtD
Trazodone—Arrhythmia—Pravastatin—atherosclerosis	0.000294	0.00276	CcSEcCtD
Trazodone—Palpitations—Ezetimibe—atherosclerosis	0.000294	0.00276	CcSEcCtD
Trazodone—Paraesthesia—Rosuvastatin—atherosclerosis	0.000293	0.00275	CcSEcCtD
Trazodone—Anaemia—Simvastatin—atherosclerosis	0.000293	0.00275	CcSEcCtD
Trazodone—Alopecia—Pravastatin—atherosclerosis	0.000291	0.00273	CcSEcCtD
Trazodone—Prochlorperazine—HRH1—atherosclerosis	0.00029	0.0687	CrCbGaD
Trazodone—Chest pain—Lovastatin—atherosclerosis	0.000289	0.00271	CcSEcCtD
Trazodone—Myalgia—Lovastatin—atherosclerosis	0.000289	0.00271	CcSEcCtD
Trazodone—Arthralgia—Lovastatin—atherosclerosis	0.000289	0.00271	CcSEcCtD
Trazodone—Anxiety—Lovastatin—atherosclerosis	0.000288	0.0027	CcSEcCtD
Trazodone—Hypertension—Ezetimibe—atherosclerosis	0.000287	0.0027	CcSEcCtD
Trazodone—Flatulence—Niacin—atherosclerosis	0.000287	0.00269	CcSEcCtD
Trazodone—Malaise—Simvastatin—atherosclerosis	0.000286	0.00269	CcSEcCtD
Trazodone—Tension—Niacin—atherosclerosis	0.000286	0.00268	CcSEcCtD
Trazodone—Discomfort—Lovastatin—atherosclerosis	0.000285	0.00268	CcSEcCtD
Trazodone—Vertigo—Simvastatin—atherosclerosis	0.000285	0.00268	CcSEcCtD
Trazodone—Arthralgia—Ezetimibe—atherosclerosis	0.000283	0.00266	CcSEcCtD
Trazodone—Myalgia—Ezetimibe—atherosclerosis	0.000283	0.00266	CcSEcCtD
Trazodone—Chest pain—Ezetimibe—atherosclerosis	0.000283	0.00266	CcSEcCtD
Trazodone—Nervousness—Niacin—atherosclerosis	0.000283	0.00266	CcSEcCtD
Trazodone—Flatulence—Pravastatin—atherosclerosis	0.000283	0.00265	CcSEcCtD
Trazodone—Dry mouth—Lovastatin—atherosclerosis	0.000282	0.00265	CcSEcCtD
Trazodone—Tension—Pravastatin—atherosclerosis	0.000282	0.00264	CcSEcCtD
Trazodone—HTR2A—blood vessel—atherosclerosis	0.000281	0.0354	CbGeAlD
Trazodone—Dysgeusia—Pravastatin—atherosclerosis	0.000281	0.00264	CcSEcCtD
Trazodone—Discomfort—Ezetimibe—atherosclerosis	0.00028	0.00263	CcSEcCtD
Trazodone—Pain—Rosuvastatin—atherosclerosis	0.000279	0.00262	CcSEcCtD
Trazodone—Constipation—Rosuvastatin—atherosclerosis	0.000279	0.00262	CcSEcCtD
Trazodone—Confusional state—Lovastatin—atherosclerosis	0.000279	0.00262	CcSEcCtD
Trazodone—Nervousness—Pravastatin—atherosclerosis	0.000279	0.00261	CcSEcCtD
Trazodone—Dry mouth—Ezetimibe—atherosclerosis	0.000277	0.0026	CcSEcCtD
Trazodone—Vision blurred—Niacin—atherosclerosis	0.000275	0.00258	CcSEcCtD
Trazodone—Confusional state—Ezetimibe—atherosclerosis	0.000274	0.00257	CcSEcCtD
Trazodone—CYP3A7—liver—atherosclerosis	0.000272	0.0342	CbGeAlD
Trazodone—Vision blurred—Pravastatin—atherosclerosis	0.00027	0.00254	CcSEcCtD
Trazodone—Chest pain—Simvastatin—atherosclerosis	0.00027	0.00253	CcSEcCtD
Trazodone—Myalgia—Simvastatin—atherosclerosis	0.00027	0.00253	CcSEcCtD
Trazodone—Arthralgia—Simvastatin—atherosclerosis	0.00027	0.00253	CcSEcCtD
Trazodone—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000269	0.00253	CcSEcCtD
Trazodone—Anxiety—Simvastatin—atherosclerosis	0.000269	0.00253	CcSEcCtD
Trazodone—Tremor—Pravastatin—atherosclerosis	0.000269	0.00252	CcSEcCtD
Trazodone—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000267	0.00251	CcSEcCtD
Trazodone—Discomfort—Simvastatin—atherosclerosis	0.000267	0.0025	CcSEcCtD
Trazodone—Ill-defined disorder—Pravastatin—atherosclerosis	0.000266	0.0025	CcSEcCtD
Trazodone—Anaemia—Pravastatin—atherosclerosis	0.000265	0.00249	CcSEcCtD
Trazodone—Anorexia—Lovastatin—atherosclerosis	0.000264	0.00248	CcSEcCtD
Trazodone—Fluphenazine—HRH1—atherosclerosis	0.000262	0.0621	CrCbGaD
Trazodone—Vertigo—Niacin—atherosclerosis	0.000262	0.00246	CcSEcCtD
Trazodone—Syncope—Niacin—atherosclerosis	0.000261	0.00245	CcSEcCtD
Trazodone—Confusional state—Simvastatin—atherosclerosis	0.000261	0.00245	CcSEcCtD
Trazodone—Urticaria—Rosuvastatin—atherosclerosis	0.00026	0.00244	CcSEcCtD
Trazodone—Oedema—Simvastatin—atherosclerosis	0.000259	0.00243	CcSEcCtD
Trazodone—Malaise—Pravastatin—atherosclerosis	0.000259	0.00243	CcSEcCtD
Trazodone—Abdominal pain—Rosuvastatin—atherosclerosis	0.000258	0.00242	CcSEcCtD
Trazodone—Vertigo—Pravastatin—atherosclerosis	0.000258	0.00242	CcSEcCtD
Trazodone—Palpitations—Niacin—atherosclerosis	0.000258	0.00242	CcSEcCtD
Trazodone—Loss of consciousness—Niacin—atherosclerosis	0.000256	0.0024	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000252	0.00237	CcSEcCtD
Trazodone—Insomnia—Lovastatin—atherosclerosis	0.00025	0.00235	CcSEcCtD
Trazodone—Paraesthesia—Lovastatin—atherosclerosis	0.000249	0.00233	CcSEcCtD
Trazodone—Myalgia—Niacin—atherosclerosis	0.000248	0.00233	CcSEcCtD
Trazodone—Arthralgia—Niacin—atherosclerosis	0.000248	0.00233	CcSEcCtD
Trazodone—Hypertension—Pravastatin—atherosclerosis	0.000248	0.00232	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000247	0.00232	CcSEcCtD
Trazodone—Anorexia—Simvastatin—atherosclerosis	0.000247	0.00232	CcSEcCtD
Trazodone—Dyspnoea—Lovastatin—atherosclerosis	0.000247	0.00232	CcSEcCtD
Trazodone—Insomnia—Ezetimibe—atherosclerosis	0.000246	0.0023	CcSEcCtD
Trazodone—Chest pain—Pravastatin—atherosclerosis	0.000244	0.00229	CcSEcCtD
Trazodone—Myalgia—Pravastatin—atherosclerosis	0.000244	0.00229	CcSEcCtD
Trazodone—Arthralgia—Pravastatin—atherosclerosis	0.000244	0.00229	CcSEcCtD
Trazodone—Paraesthesia—Ezetimibe—atherosclerosis	0.000244	0.00229	CcSEcCtD
Trazodone—Anxiety—Pravastatin—atherosclerosis	0.000243	0.00228	CcSEcCtD
Trazodone—Dry mouth—Niacin—atherosclerosis	0.000243	0.00228	CcSEcCtD
Trazodone—Dyspnoea—Ezetimibe—atherosclerosis	0.000242	0.00227	CcSEcCtD
Trazodone—Discomfort—Pravastatin—atherosclerosis	0.000241	0.00226	CcSEcCtD
Trazodone—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000241	0.00226	CcSEcCtD
Trazodone—Decreased appetite—Lovastatin—atherosclerosis	0.000241	0.00226	CcSEcCtD
Trazodone—Fatigue—Lovastatin—atherosclerosis	0.000239	0.00224	CcSEcCtD
Trazodone—Oedema—Niacin—atherosclerosis	0.000238	0.00223	CcSEcCtD
Trazodone—Pain—Lovastatin—atherosclerosis	0.000237	0.00222	CcSEcCtD
Trazodone—Constipation—Lovastatin—atherosclerosis	0.000237	0.00222	CcSEcCtD
Trazodone—Confusional state—Pravastatin—atherosclerosis	0.000236	0.00222	CcSEcCtD
Trazodone—Decreased appetite—Ezetimibe—atherosclerosis	0.000236	0.00222	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000236	0.00221	CcSEcCtD
Trazodone—HTR2B—cardiovascular system—atherosclerosis	0.000235	0.0296	CbGeAlD
Trazodone—Asthenia—Rosuvastatin—atherosclerosis	0.000234	0.0022	CcSEcCtD
Trazodone—Insomnia—Simvastatin—atherosclerosis	0.000234	0.0022	CcSEcCtD
Trazodone—Oedema—Pravastatin—atherosclerosis	0.000234	0.0022	CcSEcCtD
Trazodone—Fatigue—Ezetimibe—atherosclerosis	0.000234	0.0022	CcSEcCtD
Trazodone—Shock—Niacin—atherosclerosis	0.000234	0.0022	CcSEcCtD
Trazodone—Paraesthesia—Simvastatin—atherosclerosis	0.000233	0.00218	CcSEcCtD
Trazodone—Pain—Ezetimibe—atherosclerosis	0.000232	0.00218	CcSEcCtD
Trazodone—Constipation—Ezetimibe—atherosclerosis	0.000232	0.00218	CcSEcCtD
Trazodone—Tachycardia—Niacin—atherosclerosis	0.000232	0.00218	CcSEcCtD
Trazodone—CYP3A7-CYP3A51P—liver—atherosclerosis	0.000231	0.0291	CbGeAlD
Trazodone—Pruritus—Rosuvastatin—atherosclerosis	0.000231	0.00217	CcSEcCtD
Trazodone—Dyspnoea—Simvastatin—atherosclerosis	0.000231	0.00217	CcSEcCtD
Trazodone—Hyperhidrosis—Niacin—atherosclerosis	0.00023	0.00216	CcSEcCtD
Trazodone—Feeling abnormal—Lovastatin—atherosclerosis	0.000228	0.00214	CcSEcCtD
Trazodone—Anorexia—Niacin—atherosclerosis	0.000227	0.00213	CcSEcCtD
Trazodone—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000226	0.00212	CcSEcCtD
Trazodone—Hyperhidrosis—Pravastatin—atherosclerosis	0.000226	0.00212	CcSEcCtD
Trazodone—Decreased appetite—Simvastatin—atherosclerosis	0.000225	0.00211	CcSEcCtD
Trazodone—Feeling abnormal—Ezetimibe—atherosclerosis	0.000224	0.0021	CcSEcCtD
Trazodone—Diarrhoea—Rosuvastatin—atherosclerosis	0.000224	0.0021	CcSEcCtD
Trazodone—Fatigue—Simvastatin—atherosclerosis	0.000223	0.0021	CcSEcCtD
Trazodone—Anorexia—Pravastatin—atherosclerosis	0.000223	0.00209	CcSEcCtD
Trazodone—Hypotension—Niacin—atherosclerosis	0.000222	0.00209	CcSEcCtD
Trazodone—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000222	0.00208	CcSEcCtD
Trazodone—Constipation—Simvastatin—atherosclerosis	0.000221	0.00208	CcSEcCtD
Trazodone—Pain—Simvastatin—atherosclerosis	0.000221	0.00208	CcSEcCtD
Trazodone—Urticaria—Lovastatin—atherosclerosis	0.00022	0.00206	CcSEcCtD
Trazodone—Body temperature increased—Lovastatin—atherosclerosis	0.000219	0.00205	CcSEcCtD
Trazodone—Abdominal pain—Lovastatin—atherosclerosis	0.000219	0.00205	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000217	0.00203	CcSEcCtD
Trazodone—Dizziness—Rosuvastatin—atherosclerosis	0.000216	0.00203	CcSEcCtD
Trazodone—Urticaria—Ezetimibe—atherosclerosis	0.000216	0.00202	CcSEcCtD
Trazodone—Insomnia—Niacin—atherosclerosis	0.000215	0.00202	CcSEcCtD
Trazodone—Abdominal pain—Ezetimibe—atherosclerosis	0.000215	0.00201	CcSEcCtD
Trazodone—Body temperature increased—Ezetimibe—atherosclerosis	0.000215	0.00201	CcSEcCtD
Trazodone—Paraesthesia—Niacin—atherosclerosis	0.000214	0.002	CcSEcCtD
Trazodone—Feeling abnormal—Simvastatin—atherosclerosis	0.000213	0.002	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000213	0.002	CcSEcCtD
Trazodone—Dyspnoea—Niacin—atherosclerosis	0.000212	0.00199	CcSEcCtD
Trazodone—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000212	0.00199	CcSEcCtD
Trazodone—Insomnia—Pravastatin—atherosclerosis	0.000212	0.00199	CcSEcCtD
Trazodone—Somnolence—Niacin—atherosclerosis	0.000211	0.00198	CcSEcCtD
Trazodone—HTR1A—cardiovascular system—atherosclerosis	0.000211	0.0265	CbGeAlD
Trazodone—Paraesthesia—Pravastatin—atherosclerosis	0.00021	0.00197	CcSEcCtD
Trazodone—Trifluoperazine—HRH1—atherosclerosis	0.00021	0.0497	CrCbGaD
Trazodone—Dyspnoea—Pravastatin—atherosclerosis	0.000209	0.00196	CcSEcCtD
Trazodone—Loxapine—HRH1—atherosclerosis	0.000208	0.0493	CrCbGaD
Trazodone—Perphenazine—HRH1—atherosclerosis	0.000207	0.0491	CrCbGaD
Trazodone—HTR2B—adipose tissue—atherosclerosis	0.000207	0.0261	CbGeAlD
Trazodone—Decreased appetite—Niacin—atherosclerosis	0.000207	0.00194	CcSEcCtD
Trazodone—Rash—Rosuvastatin—atherosclerosis	0.000206	0.00193	CcSEcCtD
Trazodone—Dermatitis—Rosuvastatin—atherosclerosis	0.000206	0.00193	CcSEcCtD
Trazodone—Urticaria—Simvastatin—atherosclerosis	0.000206	0.00193	CcSEcCtD
Trazodone—Abdominal pain—Simvastatin—atherosclerosis	0.000205	0.00192	CcSEcCtD
Trazodone—Body temperature increased—Simvastatin—atherosclerosis	0.000205	0.00192	CcSEcCtD
Trazodone—Headache—Rosuvastatin—atherosclerosis	0.000205	0.00192	CcSEcCtD
Trazodone—Hypersensitivity—Lovastatin—atherosclerosis	0.000204	0.00191	CcSEcCtD
Trazodone—Decreased appetite—Pravastatin—atherosclerosis	0.000204	0.00191	CcSEcCtD
Trazodone—Pain—Niacin—atherosclerosis	0.000203	0.00191	CcSEcCtD
Trazodone—Quetiapine—HRH1—atherosclerosis	0.000203	0.0482	CrCbGaD
Trazodone—Fatigue—Pravastatin—atherosclerosis	0.000202	0.00189	CcSEcCtD
Trazodone—Pain—Pravastatin—atherosclerosis	0.0002	0.00188	CcSEcCtD
Trazodone—Constipation—Pravastatin—atherosclerosis	0.0002	0.00188	CcSEcCtD
Trazodone—Hypersensitivity—Ezetimibe—atherosclerosis	0.0002	0.00188	CcSEcCtD
Trazodone—Asthenia—Lovastatin—atherosclerosis	0.000199	0.00186	CcSEcCtD
Trazodone—Pruritus—Lovastatin—atherosclerosis	0.000196	0.00184	CcSEcCtD
Trazodone—Asthenia—Ezetimibe—atherosclerosis	0.000195	0.00183	CcSEcCtD
Trazodone—Gastrointestinal pain—Niacin—atherosclerosis	0.000194	0.00182	CcSEcCtD
Trazodone—ADRA1A—cardiovascular system—atherosclerosis	0.000194	0.0244	CbGeAlD
Trazodone—Nausea—Rosuvastatin—atherosclerosis	0.000194	0.00182	CcSEcCtD
Trazodone—Feeling abnormal—Pravastatin—atherosclerosis	0.000193	0.00181	CcSEcCtD
Trazodone—Pruritus—Ezetimibe—atherosclerosis	0.000192	0.0018	CcSEcCtD
Trazodone—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000191	0.0018	CcSEcCtD
Trazodone—Hypersensitivity—Simvastatin—atherosclerosis	0.000191	0.00179	CcSEcCtD
Trazodone—Diarrhoea—Lovastatin—atherosclerosis	0.000189	0.00178	CcSEcCtD
Trazodone—Urticaria—Niacin—atherosclerosis	0.000189	0.00177	CcSEcCtD
Trazodone—Body temperature increased—Niacin—atherosclerosis	0.000188	0.00176	CcSEcCtD
Trazodone—Abdominal pain—Niacin—atherosclerosis	0.000188	0.00176	CcSEcCtD
Trazodone—Urticaria—Pravastatin—atherosclerosis	0.000186	0.00175	CcSEcCtD
Trazodone—Asthenia—Simvastatin—atherosclerosis	0.000186	0.00174	CcSEcCtD
Trazodone—Diarrhoea—Ezetimibe—atherosclerosis	0.000186	0.00174	CcSEcCtD
Trazodone—Abdominal pain—Pravastatin—atherosclerosis	0.000185	0.00174	CcSEcCtD
Trazodone—Body temperature increased—Pravastatin—atherosclerosis	0.000185	0.00174	CcSEcCtD
Trazodone—ABCB1—blood vessel—atherosclerosis	0.000184	0.0232	CbGeAlD
Trazodone—Pruritus—Simvastatin—atherosclerosis	0.000183	0.00172	CcSEcCtD
Trazodone—Dizziness—Lovastatin—atherosclerosis	0.000183	0.00172	CcSEcCtD
Trazodone—Dizziness—Ezetimibe—atherosclerosis	0.00018	0.00169	CcSEcCtD
Trazodone—Diarrhoea—Simvastatin—atherosclerosis	0.000177	0.00166	CcSEcCtD
Trazodone—Vomiting—Lovastatin—atherosclerosis	0.000176	0.00165	CcSEcCtD
Trazodone—Hypersensitivity—Niacin—atherosclerosis	0.000175	0.00164	CcSEcCtD
Trazodone—Clozapine—HRH1—atherosclerosis	0.000175	0.0414	CrCbGaD
Trazodone—Rash—Lovastatin—atherosclerosis	0.000175	0.00164	CcSEcCtD
Trazodone—Dermatitis—Lovastatin—atherosclerosis	0.000174	0.00164	CcSEcCtD
Trazodone—Headache—Lovastatin—atherosclerosis	0.000173	0.00163	CcSEcCtD
Trazodone—HRH1—connective tissue—atherosclerosis	0.000173	0.0217	CbGeAlD
Trazodone—Vomiting—Ezetimibe—atherosclerosis	0.000173	0.00162	CcSEcCtD
Trazodone—Hypersensitivity—Pravastatin—atherosclerosis	0.000173	0.00162	CcSEcCtD
Trazodone—ORM1—liver—atherosclerosis	0.000172	0.0217	CbGeAlD
Trazodone—Dizziness—Simvastatin—atherosclerosis	0.000171	0.00161	CcSEcCtD
Trazodone—Rash—Ezetimibe—atherosclerosis	0.000171	0.00161	CcSEcCtD
Trazodone—ADRA1A—adipose tissue—atherosclerosis	0.000171	0.0215	CbGeAlD
Trazodone—Dermatitis—Ezetimibe—atherosclerosis	0.000171	0.00161	CcSEcCtD
Trazodone—Asthenia—Niacin—atherosclerosis	0.000171	0.0016	CcSEcCtD
Trazodone—Headache—Ezetimibe—atherosclerosis	0.00017	0.0016	CcSEcCtD
Trazodone—ADRA2A—connective tissue—atherosclerosis	0.00017	0.0214	CbGeAlD
Trazodone—Pruritus—Niacin—atherosclerosis	0.000168	0.00158	CcSEcCtD
Trazodone—Asthenia—Pravastatin—atherosclerosis	0.000168	0.00158	CcSEcCtD
Trazodone—Pruritus—Pravastatin—atherosclerosis	0.000166	0.00155	CcSEcCtD
Trazodone—Vomiting—Simvastatin—atherosclerosis	0.000165	0.00155	CcSEcCtD
Trazodone—Nausea—Lovastatin—atherosclerosis	0.000164	0.00154	CcSEcCtD
Trazodone—Rash—Simvastatin—atherosclerosis	0.000163	0.00153	CcSEcCtD
Trazodone—Dermatitis—Simvastatin—atherosclerosis	0.000163	0.00153	CcSEcCtD
Trazodone—Diarrhoea—Niacin—atherosclerosis	0.000163	0.00153	CcSEcCtD
Trazodone—Headache—Simvastatin—atherosclerosis	0.000162	0.00152	CcSEcCtD
Trazodone—Nausea—Ezetimibe—atherosclerosis	0.000161	0.00151	CcSEcCtD
Trazodone—Diarrhoea—Pravastatin—atherosclerosis	0.00016	0.0015	CcSEcCtD
Trazodone—Dizziness—Niacin—atherosclerosis	0.000157	0.00148	CcSEcCtD
Trazodone—Dizziness—Pravastatin—atherosclerosis	0.000155	0.00145	CcSEcCtD
Trazodone—Nausea—Simvastatin—atherosclerosis	0.000154	0.00144	CcSEcCtD
Trazodone—Vomiting—Niacin—atherosclerosis	0.000151	0.00142	CcSEcCtD
Trazodone—Rash—Niacin—atherosclerosis	0.00015	0.00141	CcSEcCtD
Trazodone—Dermatitis—Niacin—atherosclerosis	0.00015	0.00141	CcSEcCtD
Trazodone—Headache—Niacin—atherosclerosis	0.000149	0.0014	CcSEcCtD
Trazodone—Vomiting—Pravastatin—atherosclerosis	0.000149	0.0014	CcSEcCtD
Trazodone—Rash—Pravastatin—atherosclerosis	0.000148	0.00139	CcSEcCtD
Trazodone—Dermatitis—Pravastatin—atherosclerosis	0.000147	0.00138	CcSEcCtD
Trazodone—Headache—Pravastatin—atherosclerosis	0.000147	0.00138	CcSEcCtD
Trazodone—HTR2A—connective tissue—atherosclerosis	0.000144	0.0182	CbGeAlD
Trazodone—Nausea—Niacin—atherosclerosis	0.000141	0.00133	CcSEcCtD
Trazodone—Nausea—Pravastatin—atherosclerosis	0.000139	0.0013	CcSEcCtD
Trazodone—CYP3A5—adipose tissue—atherosclerosis	0.000137	0.0172	CbGeAlD
Trazodone—HRH1—adipose tissue—atherosclerosis	0.000132	0.0167	CbGeAlD
Trazodone—ADRA2A—adipose tissue—atherosclerosis	0.00013	0.0164	CbGeAlD
Trazodone—HTR2A—cardiovascular system—atherosclerosis	0.000125	0.0158	CbGeAlD
Trazodone—ADRA1A—liver—atherosclerosis	0.00012	0.0151	CbGeAlD
Trazodone—CYP3A5—liver—atherosclerosis	9.57e-05	0.0121	CbGeAlD
Trazodone—ABCB1—cardiovascular system—atherosclerosis	8.22e-05	0.0104	CbGeAlD
Trazodone—HTR2A—liver—atherosclerosis	7.76e-05	0.00977	CbGeAlD
Trazodone—ABCB1—adipose tissue—atherosclerosis	7.25e-05	0.00913	CbGeAlD
Trazodone—CYP3A4—liver—atherosclerosis	7.18e-05	0.00904	CbGeAlD
Trazodone—Thioproperazine—ALB—atherosclerosis	7.12e-05	0.0169	CrCbGaD
Trazodone—CYP2D6—liver—atherosclerosis	7.07e-05	0.0089	CbGeAlD
Trazodone—ABCB1—liver—atherosclerosis	5.09e-05	0.0064	CbGeAlD
Trazodone—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	4.88e-06	8.96e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	4.86e-06	8.92e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	4.86e-06	8.92e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—AGT—atherosclerosis	4.84e-06	8.89e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—AGT—atherosclerosis	4.83e-06	8.87e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—AGT—atherosclerosis	4.83e-06	8.87e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—ALOX5—atherosclerosis	4.83e-06	8.86e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	4.75e-06	8.72e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—APOE—atherosclerosis	4.75e-06	8.71e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—LEP—atherosclerosis	4.75e-06	8.71e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—AGT—atherosclerosis	4.74e-06	8.71e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—APOE—atherosclerosis	4.74e-06	8.7e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—LEP—atherosclerosis	4.74e-06	8.7e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—APOE—atherosclerosis	4.73e-06	8.69e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—MAPK3—atherosclerosis	4.72e-06	8.67e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CAV1—atherosclerosis	4.7e-06	8.63e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—INS—atherosclerosis	4.69e-06	8.62e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CAV1—atherosclerosis	4.69e-06	8.62e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—APOA1—atherosclerosis	4.69e-06	8.61e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—CAV1—atherosclerosis	4.69e-06	8.61e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—APOA1—atherosclerosis	4.68e-06	8.6e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—APOA1—atherosclerosis	4.68e-06	8.59e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—INS—atherosclerosis	4.67e-06	8.57e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PIK3CG—atherosclerosis	4.66e-06	8.56e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—HMOX1—atherosclerosis	4.66e-06	8.55e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—APOE—atherosclerosis	4.65e-06	8.53e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—LEP—atherosclerosis	4.65e-06	8.53e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CCL2—atherosclerosis	4.62e-06	8.48e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	4.6e-06	8.45e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	4.59e-06	8.43e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CCL2—atherosclerosis	4.59e-06	8.43e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—IGF1—atherosclerosis	4.54e-06	8.33e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—ESR1—atherosclerosis	4.53e-06	8.32e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—ESR1—atherosclerosis	4.52e-06	8.3e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—IGF1—atherosclerosis	4.52e-06	8.29e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	4.51e-06	8.29e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—CXCL8—atherosclerosis	4.5e-06	8.27e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PPARG—atherosclerosis	4.5e-06	8.26e-05	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—PTGS2—atherosclerosis	4.49e-06	8.24e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—F2—atherosclerosis	4.48e-06	8.22e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—F2—atherosclerosis	4.47e-06	8.2e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—APOB—atherosclerosis	4.46e-06	8.19e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	4.44e-06	8.15e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—INS—atherosclerosis	4.41e-06	8.1e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—AGT—atherosclerosis	4.41e-06	8.09e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—HMOX1—atherosclerosis	4.39e-06	8.06e-05	CbGpPWpGaD
Trazodone—ADRA2A—Hemostasis—AKT1—atherosclerosis	4.39e-06	8.05e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—F2—atherosclerosis	4.38e-06	8.05e-05	CbGpPWpGaD
Trazodone—HTR2B—GPCR downstream signaling—AKT1—atherosclerosis	4.35e-06	7.98e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—GSTM1—atherosclerosis	4.34e-06	7.97e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—NAMPT—atherosclerosis	4.33e-06	7.95e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—LEP—atherosclerosis	4.32e-06	7.93e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—APOE—atherosclerosis	4.32e-06	7.93e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	4.31e-06	7.91e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—LIPC—atherosclerosis	4.3e-06	7.9e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	4.29e-06	7.87e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	4.28e-06	7.86e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling by GPCR—IL6—atherosclerosis	4.28e-06	7.86e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	4.28e-06	7.85e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—APOC3—atherosclerosis	4.27e-06	7.85e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PIK3CG—atherosclerosis	4.27e-06	7.85e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PIK3CG—atherosclerosis	4.27e-06	7.84e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	4.27e-06	7.84e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—LPL—atherosclerosis	4.26e-06	7.82e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—LDLR—atherosclerosis	4.25e-06	7.8e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—APOB—atherosclerosis	4.2e-06	7.72e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	4.19e-06	7.7e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—GPX1—atherosclerosis	4.16e-06	7.63e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CETP—atherosclerosis	4.15e-06	7.62e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	4.12e-06	7.57e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PPARG—atherosclerosis	4.12e-06	7.57e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—NOS3—atherosclerosis	4.12e-06	7.56e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	4.1e-06	7.53e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—NOS3—atherosclerosis	4.09e-06	7.52e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	4.09e-06	7.52e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—GSTM1—atherosclerosis	4.09e-06	7.51e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—F2—atherosclerosis	4.07e-06	7.48e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MMP9—atherosclerosis	4.07e-06	7.48e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—INS—atherosclerosis	4.05e-06	7.44e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—CD36—atherosclerosis	4.05e-06	7.43e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—INS—atherosclerosis	4.05e-06	7.43e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—ALB—atherosclerosis	4.04e-06	7.43e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—INS—atherosclerosis	4.04e-06	7.42e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	4.03e-06	7.4e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	4.02e-06	7.37e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—LPL—atherosclerosis	4.01e-06	7.37e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CCL2—atherosclerosis	3.99e-06	7.32e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CCL2—atherosclerosis	3.98e-06	7.31e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—SCARB1—atherosclerosis	3.97e-06	7.3e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—INS—atherosclerosis	3.97e-06	7.29e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	3.96e-06	7.27e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	3.95e-06	7.25e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—IGF1—atherosclerosis	3.92e-06	7.2e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—GPX1—atherosclerosis	3.92e-06	7.19e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—IGF1—atherosclerosis	3.91e-06	7.18e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	3.91e-06	7.17e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	3.9e-06	7.15e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—NOS3—atherosclerosis	3.87e-06	7.1e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	3.84e-06	7.05e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—MTHFR—atherosclerosis	3.84e-06	7.04e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—CD36—atherosclerosis	3.81e-06	7e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PPARA—atherosclerosis	3.76e-06	6.91e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—HMGCR—atherosclerosis	3.75e-06	6.89e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	3.73e-06	6.85e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	3.72e-06	6.84e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	3.72e-06	6.82e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—ALB—atherosclerosis	3.71e-06	6.8e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—INS—atherosclerosis	3.69e-06	6.77e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	3.66e-06	6.71e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	3.65e-06	6.7e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	3.65e-06	6.7e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—AGT—atherosclerosis	3.64e-06	6.69e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	3.63e-06	6.67e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	3.63e-06	6.66e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—STAT3—atherosclerosis	3.62e-06	6.65e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—MTHFR—atherosclerosis	3.61e-06	6.64e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—APOE—atherosclerosis	3.57e-06	6.56e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	3.57e-06	6.55e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—NOS3—atherosclerosis	3.56e-06	6.53e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—NOS3—atherosclerosis	3.55e-06	6.51e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PPARA—atherosclerosis	3.55e-06	6.51e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—NOS3—atherosclerosis	3.55e-06	6.51e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PTGS2—atherosclerosis	3.54e-06	6.5e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—CAV1—atherosclerosis	3.54e-06	6.5e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—APOA1—atherosclerosis	3.53e-06	6.48e-05	CbGpPWpGaD
Trazodone—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	3.53e-06	6.48e-05	CbGpPWpGaD
Trazodone—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	3.51e-06	6.44e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	3.48e-06	6.39e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—IL6—atherosclerosis	3.47e-06	6.37e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	3.46e-06	6.35e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—IL6—atherosclerosis	3.45e-06	6.34e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—AGT—atherosclerosis	3.43e-06	6.31e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	3.39e-06	6.22e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—APOE—atherosclerosis	3.37e-06	6.18e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	3.36e-06	6.16e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—ABCA1—atherosclerosis	3.34e-06	6.14e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—CAV1—atherosclerosis	3.33e-06	6.12e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—APOA1—atherosclerosis	3.33e-06	6.11e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MMP9—atherosclerosis	3.3e-06	6.06e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MMP9—atherosclerosis	3.29e-06	6.03e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	3.27e-06	6e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	3.25e-06	5.97e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PTGS2—atherosclerosis	3.24e-06	5.95e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	3.23e-06	5.94e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CG—atherosclerosis	3.22e-06	5.92e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	3.21e-06	5.9e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	3.2e-06	5.88e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	3.2e-06	5.87e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	3.19e-06	5.85e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	3.15e-06	5.79e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CXCL8—atherosclerosis	3.15e-06	5.78e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PPARG—atherosclerosis	3.11e-06	5.71e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	3.09e-06	5.67e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—INS—atherosclerosis	3.05e-06	5.6e-05	CbGpPWpGaD
Trazodone—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	3.05e-06	5.59e-05	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	3.04e-06	5.58e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.04e-06	5.58e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—IL6—atherosclerosis	3e-06	5.51e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—IL6—atherosclerosis	2.99e-06	5.49e-05	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	2.98e-06	5.48e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	2.97e-06	5.44e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	2.95e-06	5.42e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	2.94e-06	5.39e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—STAT3—atherosclerosis	2.94e-06	5.39e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PPARG—atherosclerosis	2.93e-06	5.38e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—STAT3—atherosclerosis	2.92e-06	5.36e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—INS—atherosclerosis	2.87e-06	5.28e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—HMOX1—atherosclerosis	2.87e-06	5.27e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	2.87e-06	5.27e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MMP9—atherosclerosis	2.85e-06	5.24e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MMP9—atherosclerosis	2.85e-06	5.23e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	2.82e-06	5.18e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—NFKB1—atherosclerosis	2.82e-06	5.17e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.81e-06	5.15e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—ALB—atherosclerosis	2.8e-06	5.13e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	2.79e-06	5.13e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	2.79e-06	5.12e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	2.77e-06	5.09e-05	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	2.77e-06	5.09e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.77e-06	5.08e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	2.77e-06	5.08e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	2.76e-06	5.07e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.76e-06	5.07e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—APOB—atherosclerosis	2.75e-06	5.05e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	2.73e-06	5.01e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.72e-06	5e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	2.72e-06	4.99e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	2.71e-06	4.97e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.71e-06	4.97e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—NOS3—atherosclerosis	2.68e-06	4.91e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.67e-06	4.91e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—ALB—atherosclerosis	2.64e-06	4.84e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—LPL—atherosclerosis	2.62e-06	4.82e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	2.6e-06	4.77e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	2.57e-06	4.71e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	2.56e-06	4.7e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GPX1—atherosclerosis	2.56e-06	4.7e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—VEGFA—atherosclerosis	2.56e-06	4.69e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—STAT3—atherosclerosis	2.54e-06	4.66e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—STAT3—atherosclerosis	2.53e-06	4.65e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—IL6—atherosclerosis	2.53e-06	4.64e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	2.52e-06	4.63e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—NOS3—atherosclerosis	2.52e-06	4.63e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	2.52e-06	4.62e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	2.51e-06	4.61e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CD36—atherosclerosis	2.49e-06	4.58e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	2.48e-06	4.56e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PTGS2—atherosclerosis	2.45e-06	4.49e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	2.42e-06	4.45e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MAPK3—atherosclerosis	2.42e-06	4.44e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	2.37e-06	4.36e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.36e-06	4.34e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	2.35e-06	4.32e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—TGFB1—atherosclerosis	2.35e-06	4.31e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—AKT1—atherosclerosis	2.33e-06	4.28e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	2.33e-06	4.28e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PPARA—atherosclerosis	2.32e-06	4.26e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	2.31e-06	4.24e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.31e-06	4.23e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	2.3e-06	4.23e-05	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—AKT1—atherosclerosis	2.25e-06	4.14e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—AGT—atherosclerosis	2.25e-06	4.12e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	2.2e-06	4.05e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—APOE—atherosclerosis	2.2e-06	4.04e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CAV1—atherosclerosis	2.18e-06	4e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—APOA1—atherosclerosis	2.17e-06	3.99e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	2.14e-06	3.93e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—IL6—atherosclerosis	2.05e-06	3.77e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—IL6—atherosclerosis	2.04e-06	3.75e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.99e-06	3.65e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PPARG—atherosclerosis	1.92e-06	3.52e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.89e-06	3.47e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.88e-06	3.46e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—INS—atherosclerosis	1.88e-06	3.45e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—AKT1—atherosclerosis	1.78e-06	3.27e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.77e-06	3.25e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—IL6—atherosclerosis	1.77e-06	3.25e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—IL6—atherosclerosis	1.73e-06	3.19e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—ALB—atherosclerosis	1.72e-06	3.16e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—NOS3—atherosclerosis	1.65e-06	3.03e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.63e-06	3e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.63e-06	2.99e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—AKT1—atherosclerosis	1.63e-06	2.99e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—IL6—atherosclerosis	1.61e-06	2.96e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	1.6e-06	2.94e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.51e-06	2.77e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	1.49e-06	2.73e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—AKT1—atherosclerosis	1.23e-06	2.26e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—AKT1—atherosclerosis	1.16e-06	2.13e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—AKT1—atherosclerosis	7.58e-07	1.39e-05	CbGpPWpGaD
